Divisadero Street Capital Management LP Buys Shares of 234,219 ANI Pharmaceuticals, Inc. $ANIP

Divisadero Street Capital Management LP bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 234,219 shares of the specialty pharmaceutical company’s stock, valued at approximately $21,454,000. ANI Pharmaceuticals makes up approximately 0.9% of Divisadero Street Capital Management LP’s investment portfolio, making the stock its 27th biggest position.

Several other hedge funds have also modified their holdings of the company. Brevan Howard Capital Management LP bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at about $1,118,000. Aquatic Capital Management LLC bought a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $1,152,000. Algert Global LLC bought a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $479,000. Alliancebernstein L.P. lifted its position in ANI Pharmaceuticals by 1.5% during the third quarter. Alliancebernstein L.P. now owns 20,310 shares of the specialty pharmaceutical company’s stock valued at $1,860,000 after acquiring an additional 300 shares during the last quarter. Finally, Apis Capital Advisors LLC boosted its stake in ANI Pharmaceuticals by 28.1% in the third quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock valued at $15,022,000 after acquiring an additional 36,000 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Trading Down 2.8%

Shares of ANI Pharmaceuticals stock opened at $70.49 on Monday. The firm’s 50 day simple moving average is $79.12 and its two-hundred day simple moving average is $85.26. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of 20.98 and a beta of 0.52. ANI Pharmaceuticals, Inc. has a 12-month low of $56.71 and a 12-month high of $99.50. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11.

ANI Pharmaceuticals News Summary

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Zacks/analyst bullishness — A Zacks piece highlights ANIP among four biotech names to watch for upside in 2026, citing new drug approvals and pipeline progress. Another Zacks story notes the consensus of Wall Street analysts implies roughly a 44.8% upside in ANIP, which could support buying interest if fundamentals continue to improve. 4 Biotech Stocks to Watch for Potential Upside in 2026 Analysts See a 44.84% Upside in ANI (ANIP)
• Neutral Sentiment: Analyst/market coverage piece — Yahoo published a “sizing up” note after a recent share-price pullback that reviews valuation and technicals; such coverage can attract traders looking to buy a dip but doesn’t itself guarantee direction. Sizing Up ANI Pharmaceuticals After Recent Share Price Pullback
• Neutral Sentiment: Short interest data appears non‑informative — a March note shows effectively zero reported short interest (and a 0.0 days-to-cover), suggesting short activity is not currently driving the move. This item is ambiguous given the odd/empty figures provided.
• Negative Sentiment: Insider selling — Several insiders disclosed open-market sales this week: VP Meredith Cook sold 500 shares (avg ~$72.62; SEC filing), insider Christopher Mutz sold 3,162 shares (avg ~$71.64; SEC filing), and SVP Thomas Rowland sold 4,772 shares (avg ~$74.91; SEC filing). Combined, these disclosures show executives trimming positions and likely contributed to downward pressure on the stock today. Meredith Cook Form 4 Christopher Mutz Form 4 Thomas Rowland Form 4

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Krista Davis sold 2,084 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $77.53, for a total transaction of $161,572.52. Following the completion of the transaction, the senior vice president directly owned 50,993 shares of the company’s stock, valued at approximately $3,953,487.29. This trade represents a 3.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Christopher Mutz sold 5,323 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $78.02, for a total transaction of $415,300.46. Following the sale, the insider owned 84,840 shares of the company’s stock, valued at approximately $6,619,216.80. The trade was a 5.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 29,482 shares of company stock worth $2,248,424 over the last three months. Corporate insiders own 12.70% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on ANIP. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Guggenheim upped their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, Barclays started coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.